ArticleIranian journal of basic medical sciences2026
Investigation of neuroprotective and antiapoptotic effects of rosmarinic acid in an
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Rosmarinic acid (RA) exhibits anti-oxidant, anti-aging, and anti-inflammatory properties. This study aimed to investigate the effects of RA on amyloid beta (Aβ), phosphorylated tau (p-tau), α-synuclein (α-syn), Abelson tyrosine kinase (Abl), and apoptotic markers in an Materials and Methods: SH-SY5Y cells were differentiated into cholinergic neurons by all-trans retinoic acid (ATRA). CCK-8 assay was performed to determine the concentrations of Aβ, RA, and Aβ+RA on differentiated cells (D-cholinergic neurons). Then, control (D), D+Aβ, pretreatment (D+Aβ+RA), and D+RA groups were formed. Gene expression levels of apoptotic biomarkers were evaluated using qRT-PCR. Aβ, α-syn, Abl, p-tau, caspase-7 (CASP7), BAX, and cytochrome c (CYCS) protein levels were determined by ELISA. Results: CCK-8 assay showed that RA (0.5-5 µM) was non-toxic to differentiated cells, and the IC₄₀ of Aβ₁₋₄₂ was 20 µM. Pretreatment with 1.5 µM RA protected cells from Aβ-induced toxicity. Gene expression analysis revealed that apoptotic markers (BAX, BLC2, CYCS, CASP3, CASP7, FAS, FADD) were significantly increased in the D+Aβ group compared to the control, whereas their levels were markedly reduced in the D+Aβ+RA group relative to the D+Aβ group. ELISA results corroborated qRT-PCR findings for CASP7, BAX, and CYCS. Additionally, RA decreased Aβ, α-syn, and p-tau protein levels, while Abl levels increased only in the D+RA group. Conclusion: RA exhibits neuroprotective and antiapoptotic effects by modulating apoptotic markers and reducing pathological proteins in an
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.